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CYP2B6Abstract Background: Based on the randomised Euro-EWING99-R1 trial, vincristine, adri-
amycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide
(VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treat-
ment effect by gender was observed. The current exploratory study aimed at investigating the
inﬂuence of gender on treatment efﬁcacy and acute toxicity.
Patients and methods: Impact of gender on event-free survival (EFS), acute toxicity by course,
switches between treatment arms and cumulative dose of alkylating agents was evaluated in
multivariable models adjusted for age including terms to test for heterogeneity of treatment
effect by gender. The analysis of the EFS was performed on the intention-to-treat population.
Results: EFS did not signiﬁcantly differ between the 509 males and 347 females (p = 0.33), but
an interaction in terms of efﬁcacy was suspected between treatment and gender (p = 0.058):
VAC was associated with poorer EFS than VAI in males, hazard ratio (HR)
(VAC/VAI) = 1.37 [95% conﬁdence interval (CI), 0.98–1.90], contrasting with HR = 0.81
[95%CI, 0.53–1.24] in females. Severe toxicity was more frequent in females, whatever the tox-
icity type. Thirty patients switched from VAI to VAC (9/251 males, 4%, and 21/174 females,
12%) mostly due to renal toxicity, and three from VAC to VAI (2/258 males, 0.8%, and 1/173
females, 0.6%). A reduction of alkylating agent cumulative dose >20% was more frequent in
females (15% versus 9%, p = 0.005), with no major difference between VAC and VAI (10%
versus 13%, p = 0.15).
Conclusion: Differences of acute toxicity rate and cumulative doses of alkylating agents could
not explain the marginal interaction observed in the Euro-EWING99-R1 trial data. Effects of
gender-dependent polymorphism/activity of metabolic enzymes (e.g. known for CYP2B6) of
ifosfamide versus cyclophosphamide should be explored. External data are required to further
evaluate whether there is heterogeneity of alkylating agent effect by gender.
Trial numbers: NCT00987636 and EudraCT 2008-003658-13.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Alkylating agents ifosfamide and/or cyclophos-
phamide are part of the chemotherapeutic regimens in
all studies of Ewing sarcoma treatment. A beneﬁcial
synergistic eﬀect of ifosfamide with other chemothera-
peutic agents has been published [1–3]. However, data
on the value of ifosfamide as compared to cyclophos-
phamide are not consistent. We previously reported on
the randomised Euro-E.W.I.N.G.99-R1 trial, an inter-
national trial comparing non-inferiority of cyclophos-
phamide versus ifosfamide-based consolidation
regimens given after an intense induction chemotherapy,
in standard-risk localised Ewing sarcoma
(NCT00020566) [4]. Overall, it was concluded that
cyclophosphamide might be able to replace ifosfamide
in consolidation treatment of standard-risk Ewing sar-
coma. However, some uncertainty surrounding
non-inferiority of vincristine (V), actinomycin D (A),
cyclophosphamide (C) compared to VA-Ifosfamide (I)
remained at this stage, in particular because of a trend
towards a beneﬁt in favour of ifosfamide for male
patients [4]. With a p-value equal to 0.083 in the main
analysis, the interaction between treatment and gender
was considered to be a marginal interaction. However,interaction tests are known to be underpowered and it
is common practice to use a threshold of 0.10 for inter-
action tests. If alkylating treatment eﬀect truly varies
according to gender, such diﬀerences in eﬃcacy, if pro-
ven, would have a major impact on future clinical prac-
tice. The current manuscript reports an exploratory
analysis performed to investigate the inﬂuence of gender
on treatment eﬃcacy and acute toxicity and to deter-
mine whether age was a possible confounder.
2. Methods
2.1. Study design
The Euro-E.W.I.N.G.99-R1 trial was a two-parallel
group non-inferiority randomised trial of two diﬀerent con-
solidation regimens, conducted in 202 European paediatric
and adult oncology centres in 13 countries, via four
national or international cooperative groups; i.e. GPOH
(German Paediatric Oncology and Hematology), EORTC
(European Organization for Research and Treatment of
Cancer), CCLG (Children’s Cancer and Leukaemia
Group, United Kingdom (UK)) and the French groups
(i.e. SFCE, GSF-GETO (Groupe Sarcomes Franc¸ais), part
of French EORTC centres).
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localised, biopsy-proven Ewing sarcoma, classiﬁed as
standard-risk disease, i.e. either good histological
response to pre-operative treatment (<10% viable
tumour cells), and/or small tumour (<200 mL) resected
at diagnosis or with radiotherapy alone as local treat-
ment. Appropriate ethics committees approved the trial
in accordance with legislation in each country.
Induction chemotherapy was similar in all patients
and consisted of six courses of VI, doxorubicin (D), eto-
poside (E) (VIDE) [5,6]. After local treatment (surgery,
radiotherapy or both), if carried out at this time, the ﬁrst
consolidation course was common to both arms and
consisted of VAI (vincristine, adriamycin, ifosfamide),
after which treatment was allocated by randomisation
either to seven courses of VAI with ifosfamide (3 g/m2/
day) on Day 1 and Day 2, or to seven courses of VAC
(vincristine, adriamycin, cyclophosphamide) with
cyclophosphamide (1.5 g/m2/day) on Day 1. The total
dose of alkylating agents over the consolidation treat-
ment was 48 g/m2 ifosfamide in the VAI-arm versus
6 g/m2 ifosfamide plus 10.5 g/m2 cyclophosphamide in
the VAC arm, which were presumed to be equivalent.
Randomisation was balanced and stratiﬁed according
to age, gender, cooperative group and local treatment.
The sample size of the EE99-R1 trial (N = 856) was cal-
culated to test the non-inferiority of VAC compared to
VAI.
2.2. Statistical analyses
In the main analysis the primary end-point to evalu-
ate the impact of treatment was event-free survival
(EFS), deﬁned as the time from randomisation to ﬁrst
event (relapse, second malignancy or death whatever
the cause). At the cut-oﬀ date, 1st June 2012, the median
follow-up of the study population was 6.0 years. The
hazard ratio (HR) of failure associated with treatment
eﬀect (VAC versus VAI) was estimated with its 95% con-
ﬁdence interval in a multivariable Cox regression model
controlling for age, gender, cooperative group and local
treatment. In the previously published analysis, age was
included in the model as a binary variable corresponding
to the randomisation strata (< versus P25 years).
In the current exploratory analysis, the multivariable
Cox models included treatment, gender and age as main
eﬀects, and were stratiﬁed by cooperative group and
local treatment (surgery after VIDE induction with or
without postoperative radiotherapy/initial surgery of
primary/deﬁnitive radiotherapy). As age could be a con-
founding factor and misspeciﬁcation of a continuous
co-variable may impact the validity and accuracy of
model-based estimates; we examined diﬀerent codings
of the age, i.e. binary </P25, three strata centred on
puberty, or as a continuous variable (see Appendix formore details) [7,8], (see Appendix for more details).
We then estimated the HR of treatment eﬀect by gender,
by adding an interaction term to the model selected at
the previous step. In order to evaluate whether the treat-
ment by gender interaction estimate varied with age, we
also tested a third order interaction, treatment  gen-
der  age. The analysis of the EFS was performed on
the intention-to-treat population including all patients
by allocated treatment group (N = 856).
The impact of gender on acute toxicity following con-
solidation chemotherapy was investigated as well. VIDE
induction chemotherapy courses were not considered in
the analysis as they were administered before randomi-
sation, and similarly in both randomised groups acute
toxicity was assessed after each course, using a list of
21 selected items from the NCI-CTC-v2.0. [9]. Grade 4
haematological, grade >2 infection, renal, cardiac or
neurological and grade >3 of all other extra-
haematological toxicities were considered as severe.
Toxicity items were also pooled by body system. For
each toxicity item, a logistic regression was used to
model the risk of severe toxicity by treatment (VAC ver-
sus VAI), gender (males versus females), age (< versus
P25 years) and cooperative group, including an interac-
tion term between treatment and gender. Initially we
analysed toxicity data at the patient level, considering
the maximum grade for each patient over the whole con-
solidation treatment, and then at the level of the
chemotherapy courses, using a Generalised Estimated
Equation approach to take into account repeated obser-
vations per patient [10]. In the case of insuﬃcient data,
we used Firth’s approach to reduce the small sample size
bias [11]. To account for multiple comparisons, we set the
p-value threshold at 0.05 for signiﬁcant interaction tests.
In this toxicity analysis, we censored courses administered
after a switch from one treatment arm to the other.
As the dose of alkylating agent was collected for each
course, we computed the cumulative dose of alkylating
agents per metre-square over the whole consolidation
treatment. We calculated the weighted sum of both
agents, assuming equivalence of 4 g/m2 ifosfamide and
1 g/m2 cyclophosphamide. The dose reduction com-
pared to the expected cumulative dose of ifosfamide,
48 g/m2, was then modelled using an analysis of vari-
ance. A dose reduction greater than 20% was also anal-
ysed using a logistic regression model. These analyses
were adjusted for age and included patients who
switched from one treatment arm to the other in the
group they had initially been allocated to. Patients
who prematurely stopped treatment because of progres-
sion or death were excluded from this analysis.
All estimates are given with their 95% conﬁdence
intervals [95% CI] and tested with two-sided tests.
Statistical analyses were performed using SAS
Software 9.3.
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Overall, 856 patients (509 males, 59%; 347 females,
41%) were recruited between 2000 and 2010: 425 VAI
(251 males, 174 females) and 431 VAC (258 males, 173
females). Three years EFSs were 75.4% and 78.2% for
VAC and VAI treated patients, respectively [4]. As illus-
trated in the ﬁgure in the Appendix (Figure 5), males
were signiﬁcantly older than females in the study popu-
lation (mean age, 16.1 years [95%CI, 15.4–16.9] versus
14.7 [13.9–15.7] respectively, p = 0.02). Age could thus
be a confounding factor in the relationship between gen-
der and outcome.3.1. Eﬃcacy analysis
An event occurred in 231 patients. EFS curves by
gender and treatment arm are given in Fig. 1.
Comparison of the models including treatment, age
and gender as main eﬀects with diﬀerent typing of vari-
ables for age led us to consider age as a continuous vari-
able (details in Appendix). In the model including these
three main eﬀects with no interaction term, age was the
only factor associated with a signiﬁcant impact on the
risk of failure, with a poorer outcome with increasing
age, HR (/10 years) = 1.25 [1.09–1.43], p-value =
0.0017, whereas we observed a trend for a poorer out-
come in males compared to females, HR (males/fe-
males) = 1.13 [0.87–1.48], p-value = 0.36. When the
treatment by gender interaction term was added to this
model, results were consistent with the initial analysis,
with a diﬀerence of treatment eﬀect between genders
being slightly larger (HR (VAC/VAI) = 1.37 [0.98–
1.90] in males; HR (VAC/VAI) = 0.81 [0.53–1.24] in
females) than in the initial analysis, with a p-value for
the interaction test equal to 0.058 (Table 1). The diﬀer-
ence of EFS between genders was restricted to the
VAC arm: males had worse EFS than females with
VAC. This marginal interaction between treatmentFig. 1. Unadjusted event-free survival (EFS) curves by gender and
treatment group.and gender did not vary across age as the third order
interaction treatment  gender  age was not signiﬁ-
cant, p-value = 0.79. This result is illustrated by the
forest-plot (Fig. 2).3.2. Toxicity analyses
As detailed in Table 2 for the toxicity observed per
patient, more females than males experienced severe tox-
icities, with Odds Ratio (males/females) lower than one
for all but one toxicity item. This higher risk of severe
toxicity in females was signiﬁcant for many toxicity
types, such as haematological, infectious, renal toxicity.
We observed an increased risk of haematological toxic-
ity and a decreased risk of renal toxicity with VAC com-
pared to VAI. As illustrated by the forest plot (Fig. 3),
the eﬀect of treatment VAC versus VAI on the risk of
toxicity did not signiﬁcantly diﬀer between genders;
none of the treatment by gender interaction tests was
signiﬁcant. Overall conclusions were similar in the anal-
ysis of toxicity at the level of courses (details in
Appendix).3.3. Cumulative dose of alkylating agents
Thirty patients switched from VAI to VAC (9/251
males, 4%, and 21/174 females, 12%), mostly due to
renal toxicity, and three from VAC to VAI (2/258 males,
0.8%, and 1/173 females, 0.6%).
The variation of cumulative dose of alkylating agents
compared to the theoretical dose was not signiﬁcantly
diﬀerent between treatment arms (mean = 6.9%
[95%CI, 8.1; 5.6] in the VAC arm versus 7.9%
[9.2; 6.7] in VAI-arm, p = 0.23), while females
received signiﬁcantly lower cumulative doses than males
(8.8% [10.2; 7.4] versus 6.1% [7.2; 4.9],
p = 0.003) (Fig. 4). The diﬀerence between genders was
similar in VAC and VAI arms (interaction test,
p = 0.96). A dose reduction greater than 20% was more
frequent in females than in males (15% versus 9%, OR
(males/females) = 0.53 [0.34–0.82], p = 0.005), with no
major diﬀerence between VAC and VAI (10% versus
13%, OR(VAC/VAI) = 0.73 [0.47–1.13], p = 0.15), and
no signiﬁcant interaction between gender and treatment
eﬀect, p = 0.37.4. Discussion
As the randomisation was balanced and stratiﬁed
according to gender, we were able to evaluate diﬀerences
in outcome and toxicity between cyclophosphamide and
ifosfamide with respect to gender. EFS analysis showed
a marginal interaction between treatment eﬀect and gen-
der (p = 0.058): Males had a poorer outcome with VAC
as compared to VAI, HR (VAC/VAI) = 1.37 [0.98–
1.90], contrasting with HR = 0.81 [0.53–1.24] in females.
Table 1
Cox multivariable model of event-free survival (EFS).
Factors Hazard ratio (HR) [95% Conﬁdence interval (CI)] P-value
Age
10 year 1.26 [1.10–1.44] 0.001
Gender
Males versus Females 0.86 [0.59–1.27] 0.45
Treatment VAC versus VAI
In males 1.37 [0.98–1.90] 0.06
In females 0.81 [0.53–1.24] 0.33
The Hazard Ratios, HR, 95% conﬁdence intervals [95%CI] and p-values were estimated in a Cox multivariable model including age, gender,
treatment and treatment by gender interaction, and stratiﬁed on cooperative group and local treatment.The HR associated with age (/10 years)
corresponds to the relative increase of failure rate associated with a 10-year diﬀerence of age.AIC = 2129.
Gender by treatment interaction test, p value = 0.058.
Fig. 2. Event-free survival (EFS) analysis – Eﬀect of treatment by gender, across age categories. Age  Gender  Treatment interaction,
p-value = 0.91. *HR(VAC/VAI) = Hazard Ratio of failures associated with treatment eﬀect, estimated in model adjusted on age, in three
categories, and gender, and stratiﬁed on local treatment and cooperative group. For this analysis, age was categorised in three categories in order to
illustrate the results by a forest plot. Interaction HR = Ratio between HR(VAC/VAI) in males and HR(VAC/VAI) in females. 95% CI: 95%
Conﬁdence Intervals. The vertical dotted line represents the HR estimated on the whole population in multivariable analysis.
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Table 2
Proportion of patients who experienced a severe toxicity, by gender and treatment group, and Odds-Ratio estimated in multivariable models.
Toxicity item N Observed percentages Multivariable model
Males Females Gender eﬀect Treatment eﬀect in males Treatment eﬀect in females Inter







% % % %
Haematology grade 4 808 73 80 86 90 0.44 [0.25–0.75] 0.003 1.53 [0.99–2.36] 0.05 1.49 [0.74–3.00] 0.26 0.95
Anaemia 808 5 8 20 17 0.20 [0.10–0.41] <.0001 1.69 [0.80–3.58] 0.17 0.82 [0.46–1.45] 0.49 0.13
Leucopaenia 808 54 62 74 80 0.42 [0.27–0.65] 0.0001 1.43 [0.99–2.06] 0.06 1.39 [0.82–2.35] 0.22 0.93
Neutropenia 764 72 77 80 87 0.69 [0.42–1.15] 0.15 1.39 [0.89–2.16] 0.15 1.85 [0.97–3.52] 0.06 0.47
Thrombocytopenia 808 27 42 45 49 0.46 [0.30–0.70] 0.0003 1.98 [1.34–2.91] 0.001 1.21 [0.78–1.89] 0.40 0.10
Infection grade P2 807 34 41 47 47 0.58 [0.38–0.89] 0.01 1.37 [0.94–2.00] 0.11 1.00 [0.64–1.57] 1.00 0.30
General condition grade
P3
789 7 6 10 5 0.71 [0.34–1.48] 0.36 0.84 [0.40–1.76] 0.64 0.51 [0.21–1.23] 0.13 0.40
Gut toxicity grade P3 807 7 9 13 9 0.50 [0.25–0.99] 0.05 1.31 [0.67–2.59] 0.43 0.67 [0.33–1.38] 0.28 0.18
Stomatitis 806 2 2 4 4 0.53 [0.16–1.78] 0.31 0.97 [0.28–3.40] 0.96 1.00 [0.32–3.19] 0.99 0.97
Vomiting 806 5 5 8 4 0.54 [0.24–1.25] 0.15 1.08 [0.47–2.49] 0.86 0.52 [0.20–1.34] 0.18 0.26
Diarrhoea 806 0 2 3 1 0.18 [0.03–0.98] 0.05 2.98 [0.53–16.8] 0.21 0.27 [0.05–1.48] 0.13 0.05
Skin toxicity grade P3 805 3 1 4 2 0.68 [0.23–1.98] 0.48 0.52 [0.15–1.84] 0.31 0.53 [0.15–1.90] 0.33 0.99
Renal toxicity grade P2 806 16 12 29 15 0.49 [0.30–0.80] 0.004 0.69 [0.41–1.16] 0.16 0.44 [0.25–0.77] 0.004 0.25
Serum creatinine 805 1 2 3 3 0.30 [0.07–1.26] 0.10 1.74 [0.40–7.62] 0.46 0.81 [0.24–2.71] 0.73 0.43
Proteinuria 691 1 1 4 2 0.16 [0.03–0.86] 0.03 1.48 [0.22–9.98] 0.69 0.53 [0.15–1.87] 0.33 0.38
Haematuria 711 0 2 4 3 0.11 [0.01–0.94] 0.04 3.87 [0.43–34.9] 0.23 0.66 [0.18–2.42] 0.53 0.18
Glomerular ﬁltration 611 3 1 6 3 0.53 [0.18–1.57] 0.25 0.25 [0.04–1.40] 0.12 0.48 [0.14–1.68] 0.25 0.54
Tubular function 432 25 16 39 16 0.54 [0.30–0.98] 0.04 0.54 [0.28–1.02] 0.06 0.28 [0.13–0.60] 0.001 0.20
Hepatic toxicity grade
P3
802 4 6 7 4 0.54 [0.22–1.32] 0.18 1.66 [0.73–3.80] 0.23 0.64 [0.25–1.66] 0.36 0.14
Hyperbilirubinemia 769 1 2 5 1 0.21 [0.05–0.85] 0.03 1.82 [0.41–8.05] 0.43 0.32 [0.08–1.30] 0.11 0.10
Transaminase
elevation
798 3 5 4 3 0.80 [0.28–2.28] 0.67 1.55 [0.62–3.89] 0.35 0.87 [0.28–2.73] 0.82 0.44
Cardiac toxicity grade
P2
657 3 3 7 2 0.45 [0.15–1.31] 0.14 1.06 [0.33–3.39] 0.92 0.35 [0.09–1.32] 0.12 0.22
Cardiac function 628 2 2 1 0 1.83 [0.31–11.0] 0.51 0.98 [0.25–3.91] 0.98 0.35 [0.02–6.73] 0.49 0.54
LV-SF impairment 512 3 3 8 3 0.32 [0.10–1.11] 0.07 1.09 [0.26–4.49] 0.91 0.44 [0.11–1.74] 0.24 0.37
Neurotoxicity grade P2 805 5 7 11 8 0.34 [0.15–0.75] 0.01 1.62 [0.73–3.57] 0.23 0.62 [0.28–1.34] 0.22 0.09
Central neurotoxicity 804 1 1 3 1 0.47 [0.12–1.81] 0.28 0.71 [0.16–3.26] 0.66 0.32 [0.06–1.87] 0.21 0.50
Peripheral
neurotoxicity
803 3 7 9 7 0.30 [0.12–0.73] 0.01 2.26 [0.95–5.40] 0.07 0.69 [0.30–1.57] 0.37 0.05
The Odds Ratios, OR, 95% conﬁdence intervals [CI] and p-values (Wald test), P, were estimated in multivariable logistic regressions including age (<,P25 years), gender, cooperative group, treatment
and treatment by gender interaction.N: number of patients included in the toxicity analysis. As we excluded courses administered after a switch from one treatment arm to the other, patients who did
not receive any course allocated by randomisation are excluded. The denominator N varies across the table due to missing information for some speciﬁc toxicity items.















































Fig. 3. Toxicity analysis – Eﬀect of treatment by gender on the diﬀerent toxicity items. Left and right panels represent gender eﬀect and treatment
eﬀect according to gender, respectively. Odds ratios were estimated in the multivariable models including treatment, gender, treatment-by-gender
interaction, age, cooperative group. Each eﬀect was estimated for a toxicity category, separately. 95%CI: 95% Conﬁdence Intervals. The vertical
lines represent the null hypothesis (no gender eﬀect for the left panel, no treatment eﬀect for the right panel).
Fig. 4. Box plot of the cumulative alkylating doses compared to
protocol dose, by treatment group and by gender. The bottom and top
edges of the box indicate the ﬁrst and third quartiles. The diamond and
line inside the box indicate the mean and the median, respectively. The
whiskers indicate the minimum value (respectively, maximum) higher
(respectively, lower) than Q1-1.5*IQR (respectively, Q3+1.5*IQR)
with IQR denoting the interquartile range.
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with diﬀerent typing of this variable) in the multivari-
able model, as well as across age. Severe toxicity was
more frequent in females than in males, whatever thetoxicity type, with no signiﬁcant interaction between
treatment and gender eﬀect.
Our study has a number of strengths. It is based on
data from a large cohort, with outcomes collected
prospectively. The treatments tested were allocated by
randomisation, which was stratiﬁed by gender and age.
Our data allowed us to disentangle the impact of gender
from the possible confounding eﬀect of age.
We acknowledge several limitations of our study. The
current analysis is a secondary analysis of the EE99-R1
trial which was initially designed to test the main treat-
ment eﬀect and not the interaction. Consequently, with
a total of 231 events, the study was not suﬃciently pow-
ered to detect with a high level of conﬁdence, a treat-
ment by gender interaction for the eﬃcacy or safety
end-points. Approximately 450 events would be
required to demonstrate with 80%-power a signiﬁcant
interaction with a two-sided alpha of 5% if this interac-
tion is associated with a HR of 1.7, similar to what we
have observed. With a borderline p-value of 0.058 for
the eﬀect of treatment by gender interaction on EFS,
this exploratory analysis unfortunately neither convinc-
ingly conﬁrms, nor clearly refutes the hypothesis of a
treatment by gender interaction. Although, several
authors apply a threshold of 0.10 for interaction tests
[12]. In addition, the analysis of treatment by gender
interaction on the risk of severe toxicity was limited by
2460 H. van den Berg et al. / European Journal of Cancer 51 (2015) 2453–2464the rarity of some speciﬁc toxicities leading to under-
powered analyses. Sexual maturation may be more
important on the diﬀerent outcomes than age. This
could unfortunately not be studied accurately as puber-
tal status was not fully recorded. However, results were
stable when we included in the models the recorded
pubertal status, or the age in three categories with diﬀer-
ent cut-oﬀs by gender for the pubertal category (11–
15 years in females and 13–17 in males) (data available
on request).
In the published literature a better outcome for
females versus males in various malignancies has been
suggested [13]. Even in children and adolescents, gender
diﬀerences in eﬃcacy and toxicity have been reported
[14,15]. In a report on 352 children treated for anaplastic
large cell lymphoma, Wrobel et al. report signiﬁcantly
higher rates of toxicity in females, including grade 4
haematologic toxicity and grade 3–4 stomatitis. In the
meta-analysis performed by Collins et al. including
4838 patients with osteosarcoma using a multivariable
model adjusted for age, females had a signiﬁcantly bet-
ter overall survival, a higher rate of good tumour necro-
sis and more frequent thrombocytopenia and mucositis
[15]. However, these studies are not directly informative
of an alkylating treatment by gender interaction. In
Wrobel’s study, all patients received both cyclophos-
phamide and ifosfamide. In ’Collins’ study, approxi-
mately half of the patients received an alkylating agent
which was always ifosfamide.
It is possible that gender diﬀerences in the metabo-
lism of both ifosfamide and cyclophosphamide might
contribute to a potential interaction between alkylating
treatment, gender and outcome and to the gender diﬀer-
ences in terms of acute toxicity.
Both ifosfamide and cyclophosphamide are inactive
prodrugs, with hydroxylation as a primary activating
step, mainly under CYP3A4 and CYP2B6 control,
respectively [16–19]. Increased activity of CYP2B6 is
observed in females [20–25], which could be explained
by the male-speciﬁc inhibition of the constitutive
androstane receptor (CAR) pathway by androstenol
and androstanol, resulting in a decreased expression of
CYP2B6. CAR activity does not inﬂuence CYP3A4
activity [26–34]. As a result a gender related eﬀect of vin-
cristine, mainly metabolised through CYP3A4 cannot
be expected. Of actinomycin-D no metabolites have
been disclosed and excretion itself is through urine and
bile, making a gender related eﬀect unlikely, as well.
The diﬀerences in CYP2B6 expression between genders
might have resulted in lower levels of
cyclophosphamide-derived active hydroxylated com-
pounds in males. Since we have no quantitative
CYP-RNA measurements and no pharmacokinetic
data, such substantiated proposition is speculative.
Additionally to this gender related expression a
puberty/gender based pharmacokinetic factor can beof importance. For example, it has been shown that dox-
orubicin clearance is inﬂuenced by body fat, which
changes markedly, and in diﬀerent directions at puberty
in males and females [35]. Both the metabolic and phar-
macokinetic hypothesis challenges the equivalency of
4 g/m2 of ifosfamide per 1 g/m2 cyclophosphamide in
males.
With regard to side eﬀects being more frequent in
females than in males, the higher CYP3A4 activity, as
reported in females, might lead to higher peak levels
of the neurotoxic metabolite of ifosfamide, the
N-dechlorethylated ifosfamide [36,37] and to gender dif-
ferences in neurotoxicity reported in the literature. But
the higher frequency in haematological and gastroin-
testinal toxicity as well as renal toxicity in females in
our study cannot be fully explained.
The marginal interaction between gender and type of
alkylating agent on EFS persisted in the diﬀerent analy-
ses controlling for age. For basic biological conﬁrmation
of our hypothesis, determination of RNA levels and
measurements of enzyme activities are needed. For clin-
ical proof, the diﬀerences of acute toxicity rate or cumu-
lative doses of alkylating agents between genders, as
found, are as yet insuﬃcient to explain the ﬁndings.
Additional data from other sources are required to fur-
ther evaluate the hypothesis of heterogeneity of alkylat-
ing agent eﬀect by gender.
The observations made here, even if statistically not
conclusive, warrant further research into
gender-related diﬀerences in large drug eﬃcacy studies.
If major potential diﬀerences in eﬃcacy and tolerability
between genders are not considered, future trials might
produce misleading results because of such an interac-
tion. The results reported here should be considered as
hypotheses-generating. However, if there was to be a
true interaction between the alkylating agent used and
gender, this would have a very important implication
for the treatment of future patients. Further studies,
such as another randomised trial, are therefore needed
to conﬁrm or refute the presence of an interaction. A
meta-analysis of trials evaluating both alkylating agents
is currently on-going.
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